Cipla Ltd — Q1 FY25
Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
75%Questions answered1Evaded / deflected12Questions auditedContradictedNumbers vs filing
Answered
High priority
Reason for gross margin improvement: lower RM cost or product mix?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
CFO clearly attributed gross margin improvement to product mix, not RM cost.
Read the exchange
Question
Just on the gross margin front, is it to do with relatively lower RM cost or largely to do with the product mix? If you could explain it.
Ashish Adukia, CFO
No, on gross margin it's mainly the product mix Q4 of last year, you know we had some tender products in there from CGA and other markets which were at a lower margin. So for a higher sales here we have a better mix due to which the material cost is lower.
Evasive
High priority
Any update on US inspection and timeline?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
CEO gave no specific update or timeline, just expressed hope.
no timeline givenvague hope
Read the exchange
Question
Any thoughts on advertising post U.S. inspection?
Umang Vohra, CEO
No, we don't. The inspection we have answered the queries and I think we hope to and put remedial action and we hope to hear soon.
Answered
Medium priority
R&D expense range for full year?
Asked by Kunal Dhamesha, Macquarie Capital
CEO provided a clear percentage range for R&D spend.
Read the exchange
Question
Can you suggest any range for this full year for the R&D expense?
Umang Vohra, CEO
We have always given a guidance of up to close, you know max level for us would be about 6, 6.5% of sales quarter-on-quarter but you could take 5%-6% as a good range for.
Partial answer
High priority
Internal assessment on Goa plant clearance and use of consultants?
Asked by Kunal Dhamesha, Macquarie Capital
CEO confirmed consultants and timeline but did not directly answer whether clearance requires another inspection.
no clear yes/no on inspection requirement
Read the exchange
Question
And on the Goa plant, you said that, you know, we'll share at the appropriate time, but what is the, you know, internal assessment then? Are you confident that we get the clearance without any inspection or do you think that there'll be inspection requirement once we complete our remediation measure? And are we currently employing any consultants, third party consultants for the plant IT?
Umang Vohra, CEO
Yes. So on Goa we have given various corrective and preventive actions. We have external consultants who are working with us who are experts in their field. In Goa we've been working with those experts for two years and in Indore for over a year and they continue to be with. They continue to be assisting us in our response and remedial measures. I think the FDA will come to its conclusion by end September. That's the time that we hope to hear from them further.
Partial answer
High priority
Update on US peptide approvals and Advair filing?
Asked by Kunal Dhamesha, Macquarie Capital
CEO gave launch timing but did not confirm whether approvals have been received.
no specific approval status given
Read the exchange
Question
And then just from the U.S. product pipeline in terms of the two sites that we have, what is the update there? Have we got the approval or are we waiting for the approval and the launch will be imminent post approval. And secondly on generic Advair what is the update in terms of filing from the Indore plant?
Umang Vohra, CEO
Yes, the moment we receive approval we should be launching these peptides. But I believe that the real launches will start only starting quarter three, quarter four of this year, not before that.
Answered
Medium priority
Clarification on Advair timeline: launch or filing?
Asked by Damayanti Kerai, HSBC
CFO clarified it is for filing, not launch.
Read the exchange
Question
Ashish, one clarification. This Advair timeline which you have given, that's for launch or for filing from the InvaGen site in next calendar year?
Ashish Adukia, CFO
No ANDA filing will. So we will take batches now. The filing with the six-month stability will happen probably closer to December or January.
Answered
High priority
Drivers of $25 million QoQ US revenue increase?
Asked by Damayanti Kerai, HSBC
CEO specifically named Lanreotide ANDA and albuterol as key drivers.
Read the exchange
Question
My first question is in U.S. business so this $25 million delta which you have seen quarter-over-quarter was it more driven by the existing product pickup or Lanreotide generally played a big role there.
Umang Vohra, CEO
The two, two big products made the difference. Lanreotide, the ANDA launch, the generic ANDA launch as well as the gain in albuterol market share, those were the two big contributors here. And then there was as Ashish mentioned a marginal increase in Lenalidomide.
Answered
High priority
Plan to revise EBITDA margin guidance given strong Q1?
Asked by Damayanti Kerai, HSBC
CEO clearly stated no revision to EBITDA margin guidance.
Read the exchange
Question
My second question is on very strong gross margins which you have explained earlier. Is this the sustainable rate and on back of very strong performance in first quarter do you have any plan to revise your EBITDA margin guidance for the full fiscal?
Umang Vohra, CEO
I don't think we're doing anything on the EBITDA margin guidance, but I'll let Ashish clarify on the gross margin.
Partial answer
High priority
Impact of generic Lanreotide launch on branded version?
Asked by Surya Narayan Patra, PhillipCapital
CEO gave qualitative share data but no specific revenue or volume numbers.
no quantitative opportunity size given
Read the exchange
Question
So if you can just qualitatively give some sense of how big this opportunity could be this quarter and what impact the branded antidiabetic would have seen because of this product.
Umang Vohra, CEO
Yeah, I think so. Look, the ANDA product was launched. See, overall, if you look at it, we are about 20%-22% share before the ANDA launch of the total market. The B2 has stabilized at this share, and now with the ANDA launch, I think the ANDA launch should hopefully add to this overall share.
Answered
High priority
Risk of generic Lanreotide cannibalizing 505(b)(2) share?
Asked by Neha Manpuria, Bank of America
CEO directly addressed cannibalization risk, linking it to supply constraints.
Read the exchange
Question
And given the prescription pattern does not change, is there a risk that the generic cannibalizes on the, you know, 20%-22% market share that we have with the 505(b)(2)? Is that something we should be worried about or am I thinking this incorrectly?
Umang Vohra, CEO
In a market where NEHA supply is abundant, that could happen. But in a market where supply ramp up is very slow, it's unlikely that that will happen.
Partial answer
Medium priority
Capital allocation priorities with $1 billion cash?
Asked by Neha Manpuria, Bank of America
CFO described general strategy but no concrete plans or numbers.
no specific targets or sizes given
Read the exchange
Question
My second question, you know, sitting on close to $1 billion of cash, how should we think about, you know, capital allocation for let's say slightly more medium termish growth?
Ashish Adukia, CFO
Sure. So we are all, you know, continuously looking at strategic opportunities, both India as well as outside and mainly India. So I think that scanning continues and you know, in branded generics space in India we are very keen to grow in therapies where we don't have leadership.
Answered
Medium priority
CapEx plan over next 2-3 years?
Asked by Sumit Gupta, Centrum
CEO provided a clear range for future CapEx.
Read the exchange
Question
And so from the US side, so yeah, on the, or on the overall CapEx side. So how much do you plan to invest over the next two to three years?
Umang Vohra, CEO
See, our run rate has been about, you know, INR 1,000 crore to INR 1,200 crore. So I think that would be, that will go up slightly because we're looking at, see, we've had some CapEx in the U.S. Now for the de-risking, then we're looking at some more strategic CapEx in India mainly on the respiratory side. So all this will actually take it to possibly about INR 1,500 crore to INR 1,800 crore somewhere on. That kind of range.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| US business sustainable run rate $235-240 million | 235 | 6,694 | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.